Arcturus Therapeutics Holdings Inc.
ARCT
$8.25
-$0.39-4.46%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.06M | 7.20M | 17.15M | 28.30M | 29.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.06M | 7.20M | 17.15M | 28.30M | 29.38M |
| Cost of Revenue | 21.53M | 24.48M | 23.27M | 29.58M | 34.89M |
| Gross Profit | -19.47M | -17.28M | -6.11M | -1.28M | -5.51M |
| SG&A Expenses | 9.47M | 14.03M | 10.40M | 10.34M | 11.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.99M | 38.50M | 33.66M | 39.92M | 46.21M |
| Operating Income | -28.93M | -31.31M | -16.51M | -11.62M | -16.83M |
| Income Before Tax | -26.96M | -29.08M | -13.45M | -9.18M | -14.08M |
| Income Tax Expenses | -- | -4.00K | -- | 4.00K | -- |
| Earnings from Continuing Operations | -26.96M | -29.08M | -13.45M | -9.18M | -14.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.96M | -29.08M | -13.45M | -9.18M | -14.08M |
| EBIT | -28.93M | -31.31M | -16.51M | -11.62M | -16.83M |
| EBITDA | -28.27M | -30.63M | -15.75M | -10.84M | -16.03M |
| EPS Basic | -0.95 | -1.03 | -0.49 | -0.34 | -0.52 |
| Normalized Basic EPS | -0.59 | -0.65 | -0.31 | -0.21 | -0.32 |
| EPS Diluted | -0.95 | -1.03 | -0.49 | -0.34 | -0.52 |
| Normalized Diluted EPS | -0.59 | -0.65 | -0.31 | -0.21 | -0.32 |
| Average Basic Shares Outstanding | 28.42M | 28.11M | 27.19M | 27.13M | 27.11M |
| Average Diluted Shares Outstanding | 28.42M | 28.11M | 27.19M | 27.13M | 27.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |